Robert Allen, MD, on variant monitoring, antibody development, and the company's long-term approach to patient care.
Robert Allen, PhD
Advertisement
Allen is the Chief Scientific Officer at Invivyd.
Articles by Robert Allen, PhD
Robert Allen, PhD, discusses how Pemgarda’s stability in targeting the spike protein's receptor-binding domain offers crucial protection, including immunocompromised individuals.
Invivyd’s Chief Scientific Officer Robert Allen, PhD, discusses the company’s pemivibart (Pemgarda) including its administration, how it can be used in concert with vaccines, and how it protects against newer variants.
Advertisement
Latest Updated Articles
A Monoclonal Antibodies' Prospective Place in the COVID-19 PrEP MarketPublished: October 21st 2024 | Updated:
Pemgarda Maintains Effectiveness Against Evolving SARS-CoV-2 VariantsPublished: February 3rd 2025 | Updated:
Advertisement
Advertisement
Trending on Contagion Live
1
Nearly 1 in 5 Urinary Tract Infections in Southern California Linked to Contaminated Meat
2
Top Infectious Disease News Stories Week of October 18-October 24
3
High Continued Adherence of Lenacapavir in Individuals Who Use Substances and Alcohol
4
